Press release
Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Axsome Therapeutics, Avadel Pharmaceuticals, Suven
Narcolepsy Pipeline Insight, 2025
Narcolepsy Pipeline constitutes 15+ key companies continuously working towards developing 20+ Narcolepsy treatment therapies, analyzes DelveInsight.
Narcolepsy Overview:
Narcolepsy is an uncommon, chronic neurological disorder characterized by the brain's inability to properly control sleep-wake cycles, resulting in sudden and inappropriate sleep episodes. Key symptoms include persistent daytime drowsiness, difficulty staying alert, unexpected "sleep attacks," cataplexy (a sudden, temporary loss of muscle tone often triggered by strong emotions), sleep paralysis (brief periods of immobility when falling asleep or waking up), and vivid dreams or disrupted nighttime sleep, including hypnagogic and hypnopompic hallucinations. The condition is often linked to a lack of hypocretin (also known as orexin), a brain chemical that helps maintain wakefulness. Although narcolepsy is rare and frequently underdiagnosed-making prevalence estimates challenging-symptom management is possible through lifestyle adjustments and medications, even though there is currently no cure.
"Narcolepsy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Narcolepsy Therapeutics Market.
Download narcolepsy pipeline insights report @ https://www.delveinsight.com/report-store/narcolepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the Narcolepsy Pipeline Report
*
DelveInsight's Narcolepsy pipeline report highlights a dynamic landscape, with over 15 active companies developing more than 20 pipeline therapies aimed at treating the condition.
*
In September 2025, Takeda is set to share new clinical trial data on its Orexin Agonist TAK-861, focusing on its impact on narcolepsy, at the Sleep Europe 2025 conference.
*
Leading players in this space include Axsome Therapeutics, Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, KemPharm, and others.
*
Prominent therapies currently in development include FT218, AXS-12, among others, showing promise in enhancing the narcolepsy treatment landscape.
Narcolepsy Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Narcolepsy Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Narcolepsy treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Narcolepsy market.
Download our free narcolepsy sample report @ https://www.delveinsight.com/sample-request/narcolepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Narcolepsy Emerging Drugs
*
FT218: Avadel Pharmaceuticals
*
AXS-12: Axsome therapeutics
Narcolepsy Companies
Over 15 leading companies are actively developing treatments for narcolepsy. Among these, Avadel Pharmaceuticals has the most advanced drug candidates, with one therapy currently in the preregistration phase.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Narcolepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Narcolepsy Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Narcolepsy Therapies and Key Companies: Narcolepsy Clinical Trials and advancements [https://www.delveinsight.com/report-store/narcolepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Narcolepsy Pipeline Therapeutic Assessment
- Narcolepsy Assessment by Product Type
- Narcolepsy By Stage
- Narcolepsy Assessment by Route of Administration
- Narcolepsy Assessment by Molecule Type
Download Narcolepsy Sample report to know in detail about the Narcolepsy treatment market @ Narcolepsy Therapeutic Assessment [https://www.delveinsight.com/sample-request/narcolepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Narcolepsy Current Treatment Patterns
4. Narcolepsy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Narcolepsy Late-Stage Products (Phase-III)
7. Narcolepsy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Narcolepsy Discontinued Products
13. Narcolepsy Product Profiles
14. Narcolepsy Key Companies
15. Narcolepsy Key Products
16. Dormant and Discontinued Products
17. Narcolepsy Unmet Needs
18. Narcolepsy Future Perspectives
19. Narcolepsy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Narcolepsy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/narcolepsy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=narcolepsy-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-axsome-therapeutics-avadel-pharmaceuticals-suven]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Axsome Therapeutics, Avadel Pharmaceuticals, Suven here
News-ID: 4078693 • Views: …
More Releases from ABNewswire
An overview of clinical and preclinical research in Malignant Pleural Mesothelio …
Key players include MolMed, PharmaMar, Ys Therapeutics, Merck & Co., Kissei Pharmaceutical, NovoCure, AGC Biologics, Aduro Biotech, Novartis, Bristol-Myers Squibb, TCR2 Therapeutics, Novotech Australia, AstraZeneca, Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, and ACADIA Pharmaceuticals.
Malignant Pleural Mesothelioma Pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analyzes DelveInsight.
Malignant Pleural Mesothelioma Overview:
Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the lining of the lungs. It…
Von Willebrand Disease: Clinical and Preclinical Studies, Leading Companies, The …
DelveInsight's, "Von Willebrand's Disease - Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand's Disease pipeline landscape.
Von Willebrand Disease Pipeline constitutes 3 + key companies continuously working towards developing 3+ Von Willebrand Disease treatment therapies, analyzes DelveInsight.
Von Willebrand Disease Overview:
Von Willebrand disease (VWD) is the most prevalent inherited bleeding disorder, resulting from a deficiency or malfunction of von Willebrand factor (VWF), a…
Rethinking Acne: Texas-Based Practitioner Offers Root-Cause Approach Amid Rising …
Dallas-Fort Worth, TX - Jun 23, 2025 - As the U.S. acne treatment market continues to grow-projected to reach $7.27 billion by 2030-one Texas-based consultant is offering a radically different path forward, focused not on topical fixes or pharmaceuticals, but on the body's own internal signals.
Michelle Valeri, founder of MV Skin Consulting and a best-selling author, has spent years developing a method of acne treatment that views breakouts not as…
The Historical Novel "Thunder in the Wind" investigates what happens to a people …
Author Curt Orloff's sweeping tale of deculturization delivers a timeless message of resilience, relevance, and reckoning
In Thunder in the Wind [https://www.amazon.com/Thunder-Wind-Curt-Orloff/dp/1963565347/ref=monarch_sidesheet_image], author Curt Orloff delivers an unflinching portrait of a people caught in the storm of historical transformation. Set mostly on the Fort Belknap reservation in Montana in the late 1800s, this novel explores how ordinary people responded to the tumultuous situation of an indifferent bureaucracy and a society blinded…
More Releases for Narcolepsy
Narcolepsy Drugs Market Trends and Dynamic 2028
Global Narcolepsy Drugs Market: Overview
The narcolepsy drug pipeline has been dotted with medications that can target several symptoms of neurological sleep disorder. These symptoms are characterized notably under narcolepsy type 1 and narcolepsy type 2. An array of psychostimulants have gained favor among clinicians as third-line therapy. The global narcolepsy market has made strides driven by advances adjunctive behavioral techniques.
To know Untapped Opportunities in the Market https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6068
Moreover, constant development of…
A Comprehensive Study exploring Narcolepsy Therapeutics Market
A new research study from HTF MI with title Global Narcolepsy Therapeutics Market Size, Status and Forecast 2025 provides an in-depth assessment of the Narcolepsy Therapeutics including key market trends, upcoming technologies, industry drivers, challenges, regulatory policies, key players company profiles and strategies. The research study provides forecasts for Narcolepsy Therapeutics investments till 2025.
Access Sample Copy @: https://www.htfmarketreport.com/sample-report/1181484-global-narcolepsy-therapeutics-market-4
If you are involved in the Narcolepsy Therapeutics industry or intend…
Narcolepsy Market entry and market expansion strategies
MarketResearchReports.Biz adds “Global Narcolepsy Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Narcolepsy and the growth estimates for the forecasted period.
GlobalData's clinical trial report, Narcolepsy Global Clinical Trials Review, H1, 2018" provides an overview of Narcolepsy clinical trials scenario. This report provides top line data relating to the clinical trials on Narcolepsy. Report includes an overview of…
Narcolepsy Market Trends, outlook and Opportunity Analysis 2019
Narcolepsy is a chronic neurological disorder, which is characterized by brain’s inability to control the sleep-wake cycle of an individual. This disorder is not caused due to any mental illness, but is mainly caused due to genetic abnormalities occurring from environmental factors or biologic factors. Narcoleptic individuals exhibita typical characteristic symptom, i.e. excessive daytime sleepiness (EDS), where individuals experience disturbed night sleep and abnormal daytime sleep pattern. Narcolepsy disorder is…
Narcolepsy Treatment Pipeline Review H2 2017
Pune, India, 26th October 2017: WiseGuyReports announced addition of new report, titled “Narcolepsy - Pipeline Review, H2 2017”.
Summary
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics…
Narcolepsy Market Pipeline Review, H2 2017
"The Report Narcolepsy - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2017, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime…
